Literature DB >> 21471522

MiR-29a down-regulation in ALK-positive anaplastic large cell lymphomas contributes to apoptosis blockade through MCL-1 overexpression.

Cécile Desjobert1, Marie-Hélène Renalier, Julie Bergalet, Emilie Dejean, Nicole Joseph, Anna Kruczynski, Jean Soulier, Estelle Espinos, Fabienne Meggetto, Jérome Cavaillé, Georges Delsol, Laurence Lamant.   

Abstract

Although deregulated expression of specific microRNAs (miRNAs) has been described in solid cancers and leukemias, little evidence of miRNA deregulation has been reported in ALK-positive (ALK(+)) anaplastic large cell lymphomas (ALCL). These tumors overexpress the major antiapoptotic protein myeloid cell leukemia 1 (MCL-1), a situation that could compensate for the lack of BCL-2. We report that ALK(+) ALCL cell lines and biopsy specimens (n = 20) express a low level of miR-29a and that this down-modulation requires an active NPM-ALK kinase. Murine models (transgenic mice and mouse embryonic fibroblast [MEF] cells), which allow conditional NPM-ALK fusion protein expression, showed an increase of miR-29a expression in the absence of NPM-ALK. Concordant results were observed after the abolition of NPM-ALK kinase activity (siALK or PF-2341066) in NPM-ALK(+) ALCL cell lines. In addition, we showed that low expression of miR-29a, probably through methylation repression, plays an important regulatory role in MCL-1 overexpression that could promote tumor cell survival by inhibiting apoptosis. Enforced miR-29a expression was found to modulate apoptosis through inhibition of MCL-1 expression in ALCL cell lines and in a xenografted model, with a concomitant tumor growth reduction. Thus, synthetic miR-29a represents a potential new tool to affect tumorigenesis in these lymphomas.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21471522     DOI: 10.1182/blood-2010-09-301994

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  57 in total

1.  STAT3-mediated activation of microRNA cluster 17~92 promotes proliferation and survival of ALK-positive anaplastic large cell lymphoma.

Authors:  Elisa Spaccarotella; Elisa Pellegrino; Manuela Ferracin; Cristina Ferreri; Giuditta Cuccuru; Cuiling Liu; Javeed Iqbal; Daniela Cantarella; Riccardo Taulli; Paolo Provero; Ferdinando Di Cunto; Enzo Medico; Massimo Negrini; Wing C Chan; Giorgio Inghirami; Roberto Piva
Journal:  Haematologica       Date:  2013-08-23       Impact factor: 9.941

2.  Assessment of Apoptosis Pathway in Peripheral Blood of Autistic Patients.

Authors:  Mohammad Mahdi Eftekharian; Alireza Komaki; Vahid Kholghi Oskooie; Amir Namvar; Mohammad Taheri; Soudeh Ghafouri-Fard
Journal:  J Mol Neurosci       Date:  2019-07-30       Impact factor: 3.444

3.  MicroRNAs and Glucocorticoid-Induced Apoptosis in Lymphoid Malignancies.

Authors:  Ronit Vogt Sionov
Journal:  ISRN Hematol       Date:  2013-01-29

Review 4.  Dysregulation of microRNAs and their association in the pathogenesis of T-cell lymphoma/leukemias.

Authors:  Sho Ikeda; Hiroyuki Tagawa
Journal:  Int J Hematol       Date:  2014-02-25       Impact factor: 2.490

5.  MicroRNA expression profiling identifies molecular signatures associated with anaplastic large cell lymphoma.

Authors:  Cuiling Liu; Javeed Iqbal; Julie Teruya-Feldstein; Yulei Shen; Magdalena Julia Dabrowska; Karen Dybkaer; Megan S Lim; Roberto Piva; Antonella Barreca; Elisa Pellegrino; Elisa Spaccarotella; Cynthia M Lachel; Can Kucuk; Chun-Sun Jiang; Xiaozhou Hu; Sharathkumar Bhagavathi; Timothy C Greiner; Dennis D Weisenburger; Patricia Aoun; Sherrie L Perkins; Timothy W McKeithan; Giorgio Inghirami; Wing C Chan
Journal:  Blood       Date:  2013-06-25       Impact factor: 22.113

6.  Epigenetic deregulation of miR-29a and miR-1256 by isoflavone contributes to the inhibition of prostate cancer cell growth and invasion.

Authors:  Yiwei Li; Dejuan Kong; Aamir Ahmad; Bin Bao; Gregory Dyson; Fazlul H Sarkar
Journal:  Epigenetics       Date:  2012-07-18       Impact factor: 4.528

7.  The pathobiology of the oncogenic tyrosine kinase NPM-ALK: a brief update.

Authors:  Raymond Lai; Robert J Ingham
Journal:  Ther Adv Hematol       Date:  2013-04

8.  Reversal of microRNA-150 silencing disadvantages crizotinib-resistant NPM-ALK(+) cell growth.

Authors:  Coralie Hoareau-Aveilla; Thibaud Valentin; Camille Daugrois; Cathy Quelen; Géraldine Mitou; Samuel Quentin; Jinsong Jia; Salvatore Spicuglia; Pierre Ferrier; Monica Ceccon; Sylvie Giuriato; Carlo Gambacorti-Passerini; Pierre Brousset; Laurence Lamant; Fabienne Meggetto
Journal:  J Clin Invest       Date:  2015-08-10       Impact factor: 14.808

Review 9.  Programming cancer cells for high expression levels of Mcl1.

Authors:  Franziska Ertel; Mai Nguyen; Anne Roulston; Gordon C Shore
Journal:  EMBO Rep       Date:  2013-03-12       Impact factor: 8.807

10.  NPM-ALK up-regulates iNOS expression through a STAT3/microRNA-26a-dependent mechanism.

Authors:  Haifeng Zhu; Deeksha Vishwamitra; Choladda V Curry; Roxsan Manshouri; Lixia Diao; Aarish Khan; Hesham M Amin
Journal:  J Pathol       Date:  2013-03-14       Impact factor: 7.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.